Smith & Nephew
SNN (NYSE)
Smith & Nephew, a leading manufacturer in the medical device sector with a market cap of £10.5 billion, targets a robust 6%-7% compounded annual growth rate in underlying revenue by 2028. Currently, it offers an attractive dividend yield of 2.06% and has delivered a notable 33.65% return over the past year, despite a challenging 5-year performance of -21.96%. Analysts maintain a steady outlook with a median 12-month price target of $36.75, reflecting confidence in the company's growth trajectory and financial health.
Pros:
- Strong market position in medical devices
- Consistent dividend payments
Cons:
- Negative 5-year return
- Market competition
Smith & Nephew may be suitable for long-term investors seeking exposure to the medical device sector, particularly those who value dividend income and are willing to navigate potential volatility given its mixed 5-year performance. The company's commitment to revenue growth and recent positive returns could appeal to investors looking for growth opportunities within a well-established firm.